


Kidney stone disease

Kidney stone disease, also known as **urolithiasis**, is when a solid piece of material (kidney stone) develops in the urinary tract.^[2] Kidney stones typically form in the kidney and leave the body in the urine stream.^[2] A small stone may pass without causing symptoms.^[2] If a stone grows to more than 5 millimeters (0.2 in), it can cause blockage of the ureter, resulting in severe pain in the lower back or abdomen.^{[2][7]} A stone may also result in blood in the urine, vomiting, or painful urination.^[2] About half of people who have had a kidney stone will have another within ten years.^[8]

Most stones form due to a combination of genetics and environmental factors.^[2] Risk factors include high urine calcium levels; obesity; certain foods; some medications; calcium supplements; hyperparathyroidism; gout and not drinking enough fluids.^{[2][8]} Stones form in the kidney when minerals in urine are at high concentration.^[2] The diagnosis is usually based on symptoms, urine testing, and medical imaging.^[2] Blood tests may also be useful.^[2] Stones are typically classified by their location: nephrolithiasis (in the kidney), ureterolithiasis (in the ureter), cystolithiasis (in the bladder), or by what they are made of (calcium oxalate, uric acid, struvite, cystine).^[2]

In those who have had stones, prevention is by drinking fluids such that more than two liters of urine are produced per day.^[4] If this is not effective enough, thiazide diuretic, citrate, or allopurinol may be taken.^[4] It is recommended that soft drinks containing phosphoric acid (typically colas) be avoided.^[4] When a stone causes no symptoms, no treatment is needed.^[2] Otherwise pain control is usually the first measure, using medications such as nonsteroidal anti-inflammatory drugs or opioids.^{[7][9]} Larger stones may be helped to pass with the medication tamsulosin^[10] or may require procedures such as extracorporeal shock wave lithotripsy, ureteroscopy, or percutaneous nephrolithotomy.^[2]

Kidney stone disease	
Other names	Urolithiasis, kidney stone, renal calculus, nephrolith, kidney stone disease, ^[1]
	
A kidney stone, 8 millimeters (0.3 in) in diameter	
Specialty	Urology, nephrology
Symptoms	Severe pain in the lower back or abdomen, blood in the urine, vomiting, nausea ^[2]
Causes	Genetic and environmental factors ^[2]
Diagnostic method	Based on symptoms, urine testing, medical imaging ^[2]
Differential diagnosis	Abdominal aortic aneurysm, diverticulitis, appendicitis, pyelonephritis ^[3]
Prevention	Drinking fluids such that more than two liters of urine are produced per day ^[4]
Treatment	Pain medication, extracorporeal shock wave lithotripsy, ureteroscopy, percutaneous nephrolithotomy ^[2]

Between 1% and 15% of people globally are affected by kidney stones at some point in their lives.^[8] In 2015, 22.1 million cases occurred,^[5] resulting in about 16,100 deaths.^[6] They have become more common in the Western world since the 1970s.^[8] Generally, more men are affected than women.^[2] Kidney stones have affected humans throughout history with descriptions of surgery to remove them dating from as early as 600 BC.^[1]

Frequency	22.1 million (2015) ^[5]
Deaths	16,100 (2015) ^[6]

Contents

Signs and symptoms

Risk factors

- Calcium oxalate
- Other electrolytes
- Animal protein
- Vitamins
- Other

Pathophysiology

- Hypocitraturia
- Supersaturation of urine
- Inhibitors of stone formation

Diagnosis

- Imaging studies
- Laboratory examination
- Composition
- Location
- Size

Prevention

- Dietary measures
- Urine alkalization
- Diuretics
- Allopurinol

Treatment

- Pain management
- Medical expulsive therapy
- Lithotripsy
- Surgery

Epidemiology

History

- Etymology

Research directions

Children

Other animals

See also

References

Notes

External links

Signs and symptoms

The hallmark of a stone that obstructs the ureter or renal pelvis is excruciating, intermittent pain that radiates from the flank to the groin or to the inner thigh.^[11] This pain, known as renal colic, is often described as one of the strongest pain sensations known.^[12] Renal colic caused by kidney stones is commonly accompanied by urinary urgency, restlessness, hematuria, sweating, nausea, and vomiting. It typically comes in waves lasting 20 to 60 minutes caused by peristaltic contractions of the ureter as it attempts to expel the stone.^[11]

The embryological link between the urinary tract, the genital system, and the gastrointestinal tract is the basis of the radiation of pain to the gonads, as well as the nausea and vomiting that are also common in urolithiasis.^[13] Postrenal azotemia and hydronephrosis can be observed following the obstruction of urine flow through one or both ureters.^[14]

Pain in the lower-left quadrant can sometimes be confused with diverticulitis because the sigmoid colon overlaps the ureter, and the exact location of the pain may be difficult to isolate due to the proximity of these two structures.




Diagram showing the typical location of renal colic, below the rib cage to just above the pelvis

Risk factors

Dehydration from low fluid intake is a major factor in stone formation.^{[11][15]} Obesity is a leading risk factor as well.

High dietary intake of animal protein,^[11] sodium, sugars including honey, refined sugars, fructose and high fructose corn syrup,^[16] oxalate,^[17] grapefruit juice, and apple juice may increase the risk of kidney stone formation.^[15]

Kidney stones can result from an underlying metabolic condition, such as distal renal tubular acidosis,^[18] Dent's disease,^[19] hyperparathyroidism,^[20] primary hyperoxaluria,^[21] or medullary sponge kidney. 3–20% of people who form kidney stones have medullary sponge kidney.^{[22][23]}

Kidney stones are more common in people with Crohn's disease;^[24] Crohn's disease is associated with hyperoxaluria and malabsorption of magnesium.^[25]

A person with recurrent kidney stones may be screened for such disorders. This is typically done with a 24-hour urine collection. The urine is analyzed for features that promote stone formation.^[14]

Calcium oxalate

Calcium is one component of the most common type of human kidney stones, calcium oxalate. Some studies suggest that people who take calcium or vitamin D as a dietary supplement have a higher risk of developing kidney stones. In the United States, kidney stone formation was used as an indicator of excess calcium intake by the Reference Daily Intake committee for calcium in adults.^[26]



A kidney stone (yellow) composed of calcium oxalate

In the early 1990s, a study conducted for the Women's Health Initiative in the US found that postmenopausal women who consumed 1000 mg of supplemental calcium and 400 international units of vitamin D per day for seven years had a 17% higher risk of developing kidney stones than subjects taking a placebo.^[27] The Nurses' Health Study also showed an



Spiculations, resembling the head of a morning star, can be seen for calcium oxalate monohydrate stones. Protrusions on uric acid stones are generally smaller.

association between supplemental calcium intake and kidney stone formation.^[17]

Unlike supplemental calcium, high intakes of dietary calcium do not appear to cause kidney stones and may actually protect against their development.^{[17][27]} This is perhaps related to the role of calcium in binding ingested oxalate in the gastrointestinal tract. As the amount of calcium intake decreases, the amount of oxalate available for absorption into the bloodstream increases; this oxalate is then excreted in greater amounts into the urine by the kidneys. In the urine, oxalate is a very strong promoter of calcium oxalate precipitation—about 15 times stronger than calcium.

A 2004 study found that diets low in calcium are associated with a higher overall risk for kidney stone formation.^[28] For most individuals, other risk factors for kidney stones, such as high intakes of dietary oxalates and low fluid intake, play a greater role than calcium intake.^[29]

Other electrolytes

Calcium is not the only electrolyte that influences the formation of kidney stones. For example, by increasing urinary calcium excretion, high dietary sodium may increase the risk of stone formation.^[17]

Drinking fluoridated tap water may increase the risk of kidney stone formation by a similar mechanism, though further epidemiologic studies are warranted to determine whether fluoride in drinking water is associated with an increased incidence of kidney stones.^[30] High dietary intake of potassium appears to reduce the risk of stone formation because potassium promotes the urinary excretion of citrate, an inhibitor of calcium crystal formation.^[31]

Kidney stones are more likely to develop, and to grow larger, if a person has low dietary magnesium. Magnesium inhibits stone formation.^[32]

Animal protein

Diets in Western nations typically contain a large proportion of animal protein. Eating animal protein creates an acid load that increases urinary excretion of calcium and uric acid and reduced citrate. Urinary excretion of excess sulfurous amino acids (e.g., cysteine and methionine), uric acid, and other acidic metabolites from animal protein acidifies the urine, which promotes the formation of kidney stones.^[33] Low urinary-citrate excretion is also commonly found in those with a high dietary intake of animal protein, whereas vegetarians tend to have higher levels of citrate excretion.^[17] Low urinary citrate, too, promotes stone formation.^[33]

Vitamins

The evidence linking vitamin C supplements with an increased rate of kidney stones is inconclusive.^{[34][35]} The excess dietary intake of vitamin C might increase the risk of calcium-oxalate stone formation.^[36] The link between vitamin D intake and kidney stones is also tenuous. Excessive vitamin D supplementation may increase the risk of stone formation by increasing the intestinal absorption of calcium; correction of a deficiency does not.^[17]

Other

There are no conclusive data demonstrating a cause-and-effect relationship between alcoholic beverage consumption and kidney stones. However, some people have theorized that certain behaviors associated with frequent and binge drinking can lead to dehydration, which can, in turn, lead to the development of kidney stones.^[37]

The American Urological Association has projected that global warming will lead to an increased incidence of kidney stones in the United States by expanding the "kidney stone belt" of the southern United States.^[38]

In one study, people with lymphoproliferative/myeloproliferative disorders who were treated with chemotherapy developed symptomatic kidney stones 1.8% of the time.^[39]


Pathophysiology

Hypocitraturia

Hypocitraturia or low urinary-citrate excretion (defined as less than 320 mg/day) can cause kidney stones in up to 2/3 of cases. The protective role of citrate is linked to several mechanisms; in fact, citrate reduces urinary supersaturation of calcium salts by forming soluble complexes with calcium ions and by inhibiting crystal growth and aggregation. The therapy with potassium citrate, or magnesium potassium citrate, is commonly prescribed in clinical practice in order to increase urinary citrate and to reduce stone formation rates.^[40]

Supersaturation of urine

When the urine becomes supersaturated (when the urine solvent contains more solutes than it can hold in solution) with one or more calculogenic (crystal-forming) substances, a seed crystal may form through the process of nucleation.^[22] Heterogeneous nucleation (where there is a solid surface present on which a crystal can grow) proceeds more rapidly than homogeneous nucleation (where a crystal must grow in a liquid medium with no such surface), because it requires less energy. Adhering to cells on the surface of a renal papilla, a seed crystal can grow and aggregate into an organized mass. Depending on the chemical composition of the crystal, the stone-forming process may proceed more rapidly when the urine pH is unusually high or low.^[41]



Small crystals formed in the kidney. The most common crystals are made of calcium oxalate and they are generally 4–5 mm. Staghorn kidney stones are considerably larger. 1. Calcium and oxalate come together to make the crystal nucleus. Supersaturation promotes their combination (as does inhibition.) 2. Continued deposition at the renal papillae leads to the growth of the kidney stones. 3. Kidney stones grow and collect debris. In the case where the kidney stones block all routes to the renal papillae, this can cause severe discomfort. 4. The complete staghorn stone forms and retention occurs. Smaller solids that break off can become trapped in the urinary glands causing discomfort. 5. Displaced stones travel through the ureter. If they cannot be broken down, they must be physically removed by a surgeon.

Inhibitors of stone formation

Normal urine contains chelating agents, such as citrate, that inhibit the nucleation, growth, and aggregation of calcium-containing crystals. Other endogenous inhibitors include calgranulin (an S-100 calcium-binding protein), Tamm–Horsfall protein, glycosaminoglycans, uropontin (a form of osteopontin), nephrocalcin (an acidic glycoprotein), prothrombin F1 peptide, and bikunin (uronic acid-rich protein). The biochemical mechanisms of action of these substances have not yet been thoroughly elucidated. However, when these substances fall below their normal proportions, stones can form from an aggregation of crystals.^[44]

Sufficient dietary intake of magnesium and citrate inhibits the formation of calcium oxalate and calcium phosphate stones; in addition, magnesium and citrate operate synergistically to inhibit kidney stones. Magnesium's efficacy in subduing stone formation and growth is dose-dependent.^{[17][32][45]}

Diagnosis

Diagnosis of kidney stones is made on the basis of information obtained from the history, physical examination, urinalysis, and radiographic studies.^[46] Clinical diagnosis is usually made on the basis of the location and severity of the pain, which is typically colicky in nature (comes and goes in spasmodic

waves). Pain in the back occurs when calculi produce an obstruction in the kidney.^[47] Physical examination may reveal fever and tenderness at the costovertebral angle on the affected side.^[46]



Imaging studies

In people with a history of stones, those who are less than 50 years of age and are presenting with the symptoms of stones without any concerning signs do not require helical CT scan imaging.^[48] A CT scan is also not typically recommended in children.^[49]

Otherwise a noncontrast helical CT scan with 5 millimeters (0.2 in) sections is the diagnostic method to use to detect kidney stones and confirm the diagnosis of kidney stone disease.^{[13][46][50][51][7]} All stones are detectable on CT scans except very rare stones composed of certain drug residues in the urine,^[52] such as from indinavir. Calcium-containing stones are relatively radiodense, and they can often be detected by a traditional radiograph of the abdomen that includes the kidneys, ureters, and bladder (KUB film).^[52] Some 60% of all renal stones are radiopaque.^{[50][53]} In general, calcium phosphate stones have the greatest density, followed by calcium oxalate and magnesium ammonium phosphate stones. Cystine calculi are only faintly radiodense, while uric acid stones are usually entirely radiolucent.^[54]

Where a CT scan is unavailable, an intravenous pyelogram may be performed to help confirm the diagnosis of urolithiasis. This involves intravenous injection of a contrast agent followed by a KUB film. Uroliths present in the kidneys, ureters, or bladder may be better defined by the use of this contrast agent. Stones can also be detected by a retrograde pyelogram, where a similar contrast agent is injected directly into the distal ostium of the ureter (where the ureter terminates as it enters the bladder).^[50]

Renal ultrasonography can sometimes be useful, because it gives details about the presence of hydronephrosis, suggesting that the stone is blocking the outflow of urine.^[52] Radiolucent stones, which do not appear on KUB, may show up on ultrasound imaging studies. Other advantages of renal ultrasonography include its low cost and absence of radiation exposure. Ultrasound imaging is useful for detecting stones in situations where X-rays or CT scans are discouraged, such as in children or pregnant women.^[55] Despite these advantages, renal ultrasonography in 2009 was not considered a substitute for noncontrast helical CT scan in the initial diagnostic evaluation of urolithiasis.^[51] The main reason for this is that, compared with CT, renal ultrasonography more often fails to detect small stones (especially ureteral stones) and other serious disorders that could be causing the symptoms.^[11] A 2014 study confirmed that ultrasonography rather than CT as an initial diagnostic test results in less radiation exposure and did not find any significant complications.^[56]



Bilateral kidney stones can be seen on this KUB radiograph. There are phleboliths in the pelvis, which can be misinterpreted as bladder stones.

Axial CT scan of abdomen without contrast, showing a 3-mm stone (marked by an arrow) in the left proximal ureter

Renal ultrasonograph of a stone located at the pyeloureteric junction with accompanying hydronephrosis.

Measurement of a 5.6 mm large kidney stone in soft tissue versus skeletal CT window.

Laboratory examination

Laboratory investigations typically carried out include:^{[46][51][52][57]}

- microscopic examination of the urine, which may show red blood cells, bacteria, leukocytes, urinary casts, and crystals;
- urine culture to identify any infecting organisms present in the urinary tract and sensitivity to determine the susceptibility of these organisms to specific antibiotics;
- complete blood count, looking for neutrophilia (increased neutrophil granulocyte count) suggestive of bacterial infection, as seen in the setting of struvite stones;
- renal function tests to look for abnormally high blood calcium blood levels (hypercalcemia);
- 24 hour urine collection to measure total daily urinary volume, magnesium, sodium, uric acid, calcium, citrate, oxalate, and phosphate;
- collection of stones (by urinating through a StoneScreen kidney stone collection cup or a simple tea strainer) is useful. Chemical analysis of collected stones can establish their composition, which in turn can help to guide future preventive and therapeutic management.



Struvite crystals found on microscopic examination of the urine


Composition

Kidney stone type	Population	Circumstances	Color	Sensitivity	Details
<u>Calcium oxalate</u>	80%	when urine is acidic (decreased pH) ^[58]	Black/dark brown	Radio-opaque	Some of the oxalate in urine is produced by the body. Calcium and oxalate in the diet play a part but are not the only factors that affect the formation of calcium oxalate stones. Dietary oxalate is found in many vegetables, fruits, and nuts. Calcium from bone may also play a role in kidney stone formation.
<u>Calcium phosphate</u>	5–10%	when urine is alkaline (high pH)	Dirty white	Radio-opaque	Tends to grow in alkaline urine especially when proteus bacteria are present.
<u>Uric acid</u>	5–10%	when urine is persistently acidic	Yellow/reddish brown	Radiolucent	Diets rich in animal proteins and purines: substances found naturally in all food but especially in organ meats, fish, and shellfish.
<u>Struvite</u>	10–15%	infections in the kidney	Dirty white	Radio-opaque	Prevention of struvite stones depends on staying infection-free. Diet has not been shown to affect struvite stone formation.
<u>Cystine</u>	1–2% ^[59]	rare genetic disorder	Pink/yellow	Radio-opaque	Cystine, an amino acid (one of the building blocks of protein), leaks through the kidneys and into the urine to form crystals.
<u>Xanthine</u> ^[60]		Extremely rare	Brick red	Radiolucent	

Calcium-containing stones

By far, the most common type of kidney stones worldwide contains calcium. For example, calcium-containing stones represent about 80% of all cases in the United States; these typically contain calcium oxalate either alone or in combination with calcium phosphate in the form of apatite or brushite.^{[22][44]} Factors that promote the precipitation of oxalate crystals in the urine, such as primary hyperoxaluria, are associated with the development of calcium oxalate stones.^[21] The formation of calcium phosphate stones is associated with conditions such as hyperparathyroidism^[20] and renal tubular acidosis.^[61]

Oxaluria is increased in patients with certain gastrointestinal disorders including inflammatory bowel disease such as Crohn's disease or in patients who have undergone resection of the small bowel or small-bowel bypass procedures. Oxaluria is also increased in patients who consume increased amounts of oxalate (found in vegetables and nuts). Primary hyperoxaluria is a rare autosomal recessive condition that usually presents in childhood.^[62]




Scanning electron micrograph of the surface of a kidney stone showing tetragonal crystals of Weddellite (calcium oxalate dihydrate) emerging from the amorphous central part of the stone (the horizontal length of the picture represents 0.5 mm of the figured original)

Calcium oxalate crystals in urine appear as 'envelopes' microscopically. They may also form 'dumbbells'.^[62]

Struvite stones

About 10–15% of urinary calculi are composed of struvite (ammonium magnesium phosphate, $\text{NH}_4\text{MgPO}_4 \cdot 6\text{H}_2\text{O}$).^[63] Struvite stones (also known as "infection stones," urease, or triple-phosphate stones) form most often in the presence of infection by urea-splitting bacteria. Using the enzyme urease, these organisms metabolize urea into ammonia and carbon dioxide. This alkalinizes the urine, resulting in favorable conditions for the formation of struvite stones. *Proteus mirabilis*, *Proteus vulgaris*, and *Morganella morganii* are the most common organisms isolated; less common organisms include *Ureaplasma urealyticum* and some species of *Providencia*, *Klebsiella*, *Serratia*, and *Enterobacter*. These infection stones are commonly observed in people who have factors that predispose them to urinary tract infections, such as those with spinal cord injury and other forms of neurogenic bladder, ileal conduit urinary diversion, vesicoureteral reflux, and obstructive uropathies. They are also commonly seen in people with underlying metabolic disorders, such as idiopathic hypercalciuria, hyperparathyroidism, and gout. Infection stones can grow rapidly, forming large calyceal staghorn (antler-shaped) calculi requiring invasive surgery such as percutaneous nephrolithotomy for definitive treatment.^[63]



Multiple kidney stones composed of uric acid and a small amount of calcium oxalate



A lenticular kidney stone, excreted in the urine

Struvite stones (triple-phosphate/magnesium ammonium phosphate) have a 'coffin lid' morphology by microscopy.^[62]

Uric acid stones

About 5–10% of all stones are formed from uric acid.^[18] People with certain metabolic abnormalities, including obesity,^[17] may produce uric acid stones. They also may form in association with conditions that cause hyperuricosuria (an excessive amount of uric acid in the urine) with or without hyperuricemia (an excessive amount of uric acid in the serum). They may also form in association with disorders of acid/base metabolism where the urine is excessively acidic (low pH), resulting in precipitation of uric acid crystals. A diagnosis of uric acid urolithiasis is supported by the presence of a radiolucent stone in the face of persistent urine acidity, in conjunction with the finding of uric acid crystals in fresh urine samples.^[64]

As noted above (section on calcium oxalate stones), people with inflammatory bowel disease (Crohn's disease, ulcerative colitis) tend to have hyperoxaluria and form oxalate stones. They also have a tendency to form urate stones. Urate stones are especially common after colon resection.

Uric acid stones appear as pleomorphic crystals, usually diamond-shaped. They may also look like squares or rods which are polarizable.^[62]

Other types

People with certain rare inborn errors of metabolism have a propensity to accumulate crystal-forming substances in their urine. For example, those with cystinuria, cystinosis, and Fanconi syndrome may form stones composed of cystine. Cystine stone formation can be treated with urine alkalinization and dietary protein restriction. People afflicted with xanthinuria often produce stones composed of xanthine. People afflicted with adenine phosphoribosyltransferase deficiency may produce 2,8-dihydroxyadenine stones,^[65] alkaptonurics produce homogentisic acid stones, and iminoglycinurics produce stones of glycine, proline, and hydroxyproline.^{[66][67]} Urolithiasis has also been noted to occur in the setting of therapeutic drug use, with crystals of drug forming within the renal tract in some people currently being treated with agents such as indinavir,^[68] sulfadiazine,^[69] and triamterene.^[70]

Location

Urolithiasis refers to stones originating anywhere in the urinary system, including the kidneys and bladder.^[13] Nephrolithiasis refers to the presence of such stones in the kidneys. Calyceal calculi are aggregations in either the minor or major calyx, parts of the kidney that pass urine into the ureter (the tube connecting the kidneys to the urinary bladder). The condition is called ureterolithiasis when a calculus is located in the ureter. Stones may also form or pass into the bladder, a condition referred to as bladder stones.^[71]




Illustration of kidney stones

Size

Stones less than 5 mm (0.2 in) in diameter pass spontaneously in up to 98% of cases, while those measuring 5 to 10 mm (0.2 to 0.4 in) in diameter pass spontaneously in less than 53% of cases.^[72]

Stones that are large enough to fill out the renal calyces are called *staghorn stones*, and are composed of struvite in a vast majority of cases, which forms only in the presence of urease-forming bacteria. Other forms that can possibly grow to become staghorn stones are those composed of cystine, calcium oxalate monohydrate, and uric acid.^[73]

Prevention

Preventative measures depend on the type of stones. In those with calcium stones, drinking lots of fluids, thiazide diuretics and citrate are effective as is allopurinol in those with high uric acid levels in the blood or urine.^{[74][75]}

Dietary measures



Radiograph showing a large staghorn calculus involving the major calyces and renal pelvis in a person with severe scoliosis.

Specific therapy should be tailored to the type of stones involved. Diet can have an effect on the development of kidney stones. Preventive strategies include some combination of dietary modifications and medications with the goal of reducing the excretory load of calculogenic compounds on the kidneys.^{[28][76][77]} Dietary recommendations to minimize the formation of kidney stones include:

- Increasing total fluid intake to more than two liters per day of urine output.^[78]
- Limiting cola soft drinks,^{[74][78]} to less than one liter per week.^[79]
- Limiting animal protein intake to no more than two meals daily (an association between animal protein and recurrence of kidney stones has been shown in men^[80]).

Maintenance of dilute urine by means of vigorous fluid therapy is beneficial in all forms of kidney stones, so increasing urine volume is a key principle for the prevention of kidney stones. Fluid intake should be sufficient to maintain a urine output of at least 2 litres (68 US fl oz) per day.^[75] A high fluid intake has been associated with a 40% reduction in recurrence risk.^[51] The quality of the evidence for this, however, is not very good.^[75]

Calcium binds with available oxalate in the gastrointestinal tract, thereby preventing its absorption into the bloodstream, and reducing oxalate absorption decreases kidney stone risk in susceptible people.^[81] Because of this, some doctors recommend chewing calcium tablets during meals containing oxalate foods.^[82] Calcium citrate supplements can be taken with meals if dietary calcium cannot be increased by other means. The preferred calcium supplement for people at risk of stone formation is calcium citrate because it helps to increase urinary citrate excretion.^[77]

Aside from vigorous oral hydration and eating more dietary calcium, other prevention strategies include avoidance of large doses of supplemental vitamin C and restriction of oxalate-rich foods such as leaf vegetables, rhubarb, soy products and chocolate.^[83] However, no randomized, controlled trial of oxalate restriction has been performed to test the hypothesis that oxalate restriction reduces stone formation.^[82] Some evidence indicates magnesium intake decreases the risk of symptomatic kidney stones.^[83]

Urine alkalization

The mainstay for medical management of uric acid stones is alkalization (increasing the pH) of the urine. Uric acid stones are among the few types amenable to dissolution therapy, referred to as chemolysis. Chemolysis is usually achieved through the use of oral medications, although in some cases, intravenous agents or even instillation of certain irrigating agents directly onto the stone can be performed, using antegrade nephrostomy or retrograde ureteral catheters.^[42] Acetazolamide is a medication that alkalizes the urine. In addition to acetazolamide or as an alternative, certain dietary supplements are available that produce a similar alkalization of the urine. These include sodium bicarbonate, potassium citrate, magnesium citrate, and Bicitra (a combination of citric acid monohydrate and sodium citrate dihydrate).^[84] Aside from alkalization of the urine, these supplements have the added advantage of increasing the urinary citrate level, which helps to reduce the aggregation of calcium oxalate stones.^[42]

Increasing the urine pH to around 6.5 provides optimal conditions for dissolution of uric acid stones. Increasing the urine pH to a value higher than 7.0 increases the risk of calcium phosphate stone formation. Testing the urine periodically with nitrazine paper can help to ensure the urine pH remains in this optimal range. Using this approach, stone dissolution rate can be expected to be around 10 mm (0.4 in) of stone radius per month.^[42]

Diuretics

One of the recognized medical therapies for prevention of stones is the thiazide and thiazide-like diuretics, such as chlorthalidone or indapamide. These drugs inhibit the formation of calcium-containing stones by reducing urinary calcium excretion.^[11] Sodium restriction is necessary for clinical effect of thiazides, as sodium excess promotes calcium excretion. Thiazides work best for renal leak hypercalciuria (high urine calcium levels), a condition in which high urinary calcium levels are caused by a primary kidney defect. Thiazides are useful for treating absorptive hypercalciuria, a condition in which high urinary calcium is a result of excess absorption from the gastrointestinal tract.^[44]

Allopurinol

For people with hyperuricosuria and calcium stones, allopurinol is one of the few treatments that have been shown to reduce kidney stone recurrences. Allopurinol interferes with the production of uric acid in the liver. The drug is also used in people with gout or hyperuricemia (high serum uric acid levels).^[85] Dosage is adjusted to maintain a reduced urinary excretion of uric acid. Serum uric acid level at or below 6 mg/100 ml) is often a therapeutic goal. Hyperuricemia is not necessary for the formation of uric acid stones; hyperuricosuria can occur in the presence of normal or even low serum uric acid. Some practitioners advocate adding allopurinol only in people in whom hyperuricosuria and hyperuricemia persist, despite the use of a urine-alkalinizing agent such as sodium bicarbonate or potassium citrate.^[42]

Treatment

Stone size influences the rate of spontaneous stone passage. For example, up to 98% of small stones (less than 5 mm (0.2 in) in diameter) may pass spontaneously through urination within four weeks of the onset of symptoms,^[7] but for larger stones (5 to 10 mm (0.2 to 0.4 in) in diameter), the rate of spontaneous passage decreases to less than 53%.^[72] Initial stone location also influences the likelihood of spontaneous stone passage. Rates increase from 48% for stones located in the proximal ureter to 79% for stones located at the vesicoureteric junction, regardless of stone size.^[72] Assuming no high-grade obstruction or associated infection is found in the urinary tract, and symptoms are relatively mild, various nonsurgical measures can be used to encourage the passage of a stone.^[42] Repeat stone formers benefit from more intense management, including proper fluid intake and use of certain medications, as well as careful monitoring.^[86]

Pain management

Management of pain often requires intravenous administration of NSAIDs or opioids.^[11] NSAIDs appear somewhat better than opioids or paracetamol in those with normal kidney function.^[87] Medications by mouth are often effective for less severe discomfort.^[55] The use of antispasmodics does not have further benefit.^[9]

Medical expulsive therapy

The use of medications to speed the spontaneous passage of stones in the ureter is referred to as medical expulsive therapy.^{[88][89]} Several agents, including alpha adrenergic blockers (such as tamsulosin) and calcium channel blockers (such as nifedipine), may be effective.^[88] Alpha-blockers likely result in more people passing their stones, and they may pass their stones in a shorter time.^[89] Alpha-blockers appear to

be more effective for larger stones (over 5 mm in size) than smaller stones.^[89] A combination of tamsulosin and a corticosteroid may be better than tamsulosin alone.^[88] These treatments also appear to be a useful in addition to lithotripsy.^[7]

Lithotripsy

Extracorporeal shock wave lithotripsy (ESWL) is a noninvasive technique for the removal of kidney stones. Most ESWL is carried out when the stone is present near the renal pelvis. ESWL involves the use of a lithotripter machine to deliver externally applied, focused, high-intensity pulses of ultrasonic energy to cause fragmentation of a stone over a period of around 30–60 minutes. Following its introduction in the United States in February 1984, ESWL was rapidly and widely accepted as a treatment alternative for renal and ureteral stones.^[90] It is currently used in the treatment of uncomplicated stones located in the kidney and upper ureter, provided the aggregate stone burden (stone size and number) is less than 20 mm (0.8 in) and the anatomy of the involved kidney is normal.^{[91][92]}



A lithotripter machine is seen in an operating room; other equipment is seen in the background, including an anesthesia machine and a mobile fluoroscopic system (or "C-arm").

For a stone greater than 10 mm (0.4 in), ESWL may not help break the stone in one treatment; instead, two or three treatments may be needed. Some 80 to 85% of simple renal calculi can be effectively treated with ESWL.^[7] A number of factors can influence its efficacy, including chemical composition of the stone, presence of anomalous renal anatomy and the specific location of the stone within the kidney, presence of hydronephrosis, body mass index, and distance of the stone from the surface of the skin.^[90] Common adverse effects of ESWL include acute trauma, such as bruising at the site of shock administration, and damage to blood vessels of the kidney.^{[93][94]} In fact, the vast majority of people who are treated with a typical dose of shock waves using currently accepted treatment settings are likely to experience some degree of acute kidney injury.^[90]

ESWL-induced acute kidney injury is dose-dependent (increases with the total number of shock waves administered and with the power setting of the lithotripter) and can be severe,^[90] including internal bleeding and subcapsular hematomas. On rare occasions, such cases may require blood transfusion and even lead to acute kidney failure. Hematoma rates may be related to the type of lithotripter used; hematoma rates of less than 1% and up to 13% have been reported for different lithotripter machines.^[94] Recent studies show reduced acute tissue injury when the treatment protocol includes a brief pause following the initiation of treatment, and both improved stone breakage and a reduction in injury when ESWL is carried out at slow shock wave rate.^[90]

In addition to the aforementioned potential for acute kidney injury, animal studies suggest these acute injuries may progress to scar formation, resulting in loss of functional renal volume.^{[93][94]} Recent prospective studies also indicate elderly people are at increased risk of developing new-onset hypertension following ESWL. In addition, a retrospective case-control study published by researchers from the Mayo Clinic in 2006 has found an increased risk of developing diabetes mellitus and hypertension in people who had undergone ESWL, compared with age and gender-matched people who had undergone nonsurgical treatment. Whether or not acute trauma progresses to long-term effects

probably depends on multiple factors that include the shock wave dose (i.e., the number of shock waves delivered, rate of delivery, power setting, acoustic characteristics of the particular lithotripter, and frequency of retreatment), as well as certain intrinsic predisposing pathophysiologic risk factors.^[90]


To address these concerns, the American Urological Association established the Shock Wave Lithotripsy Task Force to provide an expert opinion on the safety and risk-benefit ratio of ESWL. The task force published a white paper outlining their conclusions in 2009. They concluded the risk-benefit ratio remains favorable for many people.^[90] The advantages of ESWL include its noninvasive nature, the fact that it is technically easy to treat most upper urinary tract calculi, and that, at least acutely, it is a well-tolerated, low-morbidity treatment for the vast majority of people. However, they recommended slowing the shock wave firing rate from 120 pulses per minute to 60 pulses per minute to reduce the risk of renal injury and increase the degree of stone fragmentation.^[90]

Surgery

Most stones under 5 mm (0.2 in) pass spontaneously.^{[28][7]} Prompt surgery may, nonetheless, be required in persons with only one working kidney, bilateral obstructing stones, a urinary tract infection and thus, it is presumed, an infected kidney, or intractable pain.^[95] Beginning in the mid-1980s, less invasive treatments such as extracorporeal shock wave lithotripsy, ureteroscopy, and percutaneous nephrolithotomy began to replace open surgery as the modalities of choice for the surgical management of urolithiasis.^[7] More recently, flexible ureteroscopy has been adapted to facilitate retrograde nephrostomy creation for percutaneous nephrolithotomy. This approach is still under investigation, though early results are favorable.^[96] Percutaneous nephrolithotomy or, rarely, anatomic nephrolithotomy, is the treatment of choice for large or complicated stones (such as calyceal staghorn calculi) or stones that cannot be extracted using less invasive procedures.^{[46][7]}

Ureteroscopic surgery

Ureteroscopy has become increasingly popular as flexible and rigid fiberoptic ureteroscopes have become smaller. One ureteroscopic technique involves the placement of a ureteral stent (a small tube extending from the bladder, up the ureter and into the kidney) to provide immediate relief of an obstructed kidney. Stent placement can be useful for saving a kidney at risk for postrenal acute kidney failure due to the increased hydrostatic pressure, swelling and infection (pyelonephritis and pyonephrosis) caused by an obstructing stone. Ureteral stents vary in length from 24 to 30 cm (9.4 to 11.8 in) and most have a shape commonly referred to as a "double-J" or "double pigtail", because of the curl at both ends. They are designed to allow urine to flow past an obstruction in the ureter. They may be retained in the ureter for days to weeks as infections resolve and as stones are dissolved or fragmented by ESWL or by some



Three-dimensional reconstructed CT scan image of a ureteral stent in the left kidney (indicated by yellow arrow), with a kidney stone in the inferior renal pelvis (highest red arrow) and one in the ureter beside the stent (lower red arrow)



A kidney stone at the tip of an ultrasonic stone disintegration apparatus

other treatment. The stents dilate the ureters, which can facilitate instrumentation, and they also provide a clear landmark to aid in the visualization of the ureters and any associated stones on radiographic examinations. The presence of indwelling ureteral stents may cause minimal to moderate discomfort, frequency or urgency incontinence, and infection, which in general resolves on removal. Most ureteral stents can be removed cystoscopically during an office visit under topical anesthesia after resolution of urolithiasis.^[97]

More definitive ureteroscopic techniques for stone extraction (rather than simply bypassing the obstruction) include basket extraction and ultrasound ureterolithotripsy. Laser lithotripsy is another technique, which involves the use of a holmium:yttrium aluminium garnet (Ho:YAG) laser to fragment stones in the bladder, ureters, and kidneys.^[98]

Ureteroscopic techniques are generally more effective than ESWL for treating stones located in the lower ureter, with success rates of 93–100% using Ho:YAG laser lithotripsy.^[72] Although ESWL has been traditionally preferred by many practitioners for treating stones located in the upper ureter, more recent experience suggests ureteroscopic techniques offer distinct advantages in the treatment of upper ureteral stones. Specifically, the overall success rate is higher, fewer repeat interventions and postoperative visits are needed, and treatment costs are lower after ureteroscopic treatment when compared with ESWL. These advantages are especially apparent with stones greater than 10 mm (0.4 in) in diameter. However, because ureteroscopy of the upper ureter is much more challenging than ESWL, many urologists still prefer to use ESWL as a first-line treatment for stones of less than 10 mm, and ureteroscopy for those greater than 10 mm in diameter.^[72] Ureteroscopy is the preferred treatment in pregnant and morbidly obese people, as well as those with bleeding disorders.^[7]

Epidemiology

Kidney stones affect all geographical, cultural, and racial groups. The lifetime risk is about 10 to 15% in the developed world, but can be as high as 20 to 25% in the Middle East. The increased risk of dehydration in hot climates, coupled with a diet 50% lower in calcium and 250% higher in oxalates compared to Western diets, accounts for the higher net risk in the Middle East.^[100] In the Middle East, uric acid stones are more common than calcium-containing stones.^[22] The number of deaths due to kidney stones is estimated at 19,000 per year being fairly consistent between 1990 and 2010.^[101]


Country	Earliest prevalence (years) ^[99]	Latest prevalence (years) ^[99]
United States	2.6% (1964–1972)	5.2% (1988–1994)
Italy	1.2% (1983)	1.7% (1993–1994)
Scotland	3.8% (1977)	3.5% (1987)
Spain	0.1% (1977)	10.0% (1991)
Turkey	n/a	14.8% (1989)

Country	New cases per 100,000 (year) ^[99]	Trend
United States	116 (2000)	decreasing
Germany	720 (2000)	increasing
Japan	114.3 (2005)	increasing
Spain	270 (1984)	decreasing
Sweden	200 (1969)	increasing

In North America and Europe, the annual number of new cases per year of kidney stones is roughly 0.5%. In the United States, the frequency in the population of urolithiasis has increased from 3.2% to 5.2% from the mid-1970s to the mid-1990s.^[18] In the United States, about 9% of the population has had a kidney stone.^[2]

The total cost for treating urolithiasis was US\$2 billion in 2003.^[52] About 65–80% of those with kidney stones are men; most stones in women are due to either metabolic defects (such as cystinuria) or infection.^{[63][102]} (p. 1057) Men most commonly experience their first episode between 30 and 40 years of age, whereas for women, the age at first presentation is somewhat later.^[63] The age of onset shows a bimodal distribution in women, with episodes peaking at 35 and 55 years.^[52] Recurrence rates are estimated at 50% over a 10-year and 75% over 20-year period,^[18] with some people experiencing ten or more episodes over the course of a lifetime.^[63]

A 2010 review concluded that rates of disease are increasing.^[99]



Urolithiasis deaths per million persons in 2012



History

The existence of kidney stones was first recorded thousands of years ago, and lithotomy for the removal of stones is one of the earliest known surgical procedures.^[103] In 1901, a stone discovered in the pelvis of an ancient Egyptian mummy was dated to 4,800 BC. Medical texts from ancient Mesopotamia, India, China, Persia, Greece, and Rome all mentioned calculous disease. Part of the Hippocratic Oath suggests there were practicing surgeons in ancient Greece to whom physicians were to defer for lithotomies. The Roman medical treatise *De Medicina* by Aulus Cornelius Celsus contained a description of lithotomy,^[104] and this work served as the basis for this procedure until the 18th century.^[105]

Famous people who were kidney stone formers include Napoleon I, Epicurus, Napoleon III, Peter the Great, Louis XIV, George IV, Oliver Cromwell, Lyndon B. Johnson, Benjamin Franklin, Michel de Montaigne, Francis Bacon, Isaac Newton, Samuel Pepys, William Harvey, Herman Boerhaave, and Antonio Scarpa.^[106]

New techniques in lithotomy began to emerge starting in 1520, but the operation remained risky. After Henry Jacob Bigelow popularized the technique of litholapaxy in 1878,^[107] the mortality rate dropped from about 24% to 2.4%. However, other treatment techniques continued to produce a high level of mortality, especially among inexperienced urologists.^{[105][106]} In 1980, Dornier MedTech introduced extracorporeal shock wave lithotripsy for breaking up stones via acoustical pulses, and this technique has since come into widespread use.^[90]

Etymology

Renal calculus is from the Latin *rēnēs* meaning "kidneys," and *calculus* meaning "pebble". Lithiasis (stone formation) in the kidneys is called nephrolithiasis (/ˌnɛfroʊlɪˈθaɪəsɪs/), from *nephro-* meaning kidney + *-lith* meaning stone and *-iasis* meaning disorder.

Research directions

Crystallization of calcium oxalate appears to be inhibited by certain substances in the urine that retard the formation, growth, aggregation, and adherence of crystals to renal cells. By purifying urine using salt precipitation, isoelectric focusing, and size-exclusion chromatography, some researchers have found that calgranulin, a protein formed in the kidney, is a potent inhibitor of the *in vivo* formation of calcium oxalate crystals. Considering its extremely high levels of inhibition of growth and aggregation of calcium oxalate crystals, calgranulin might be an important intrinsic factor in the prevention of nephrolithiasis.^[108]

Children

Although kidney stones do not often occur in children, the incidence is increasing.^[109] These stones are in the kidney in two thirds of reported cases, and in the ureter in the remaining cases. Older children are at greater risk independent of sex.^[110]

As with adults, most pediatric kidney stones are predominantly composed of calcium oxalate; struvite and calcium phosphate stones are less common. Calcium oxalate stones in children are associated with high amounts of calcium, oxalate, and magnesium in acidic urine.^[111]

Other animals

Among ruminants, uroliths more commonly cause problems in males than in females; the sigmoid flexure of the ruminant male urinary tract is more likely to obstruct passage. Early-castrated males are at greater risk, because of lesser urethral diameter.^[112]

Low Ca:P intake ratio is conducive to phosphatic (e.g. struvite) urolith formation.^[112] Incidence among wether lambs can be minimized by maintaining a dietary Ca:P intake ratio of 2:1.^{[112][113]}

Alkaline (higher) pH favors formation of carbonate and phosphate calculi. For domestic ruminants, dietary cation: anion balance is sometimes adjusted to assure a slightly acidic urine pH, for prevention of calculus formation^[112]

Differing generalizations regarding effects of pH on formation of silicate uroliths may be found.^{[112][114]} In this connection, it may be noted that under some circumstances, calcium carbonate accompanies silica in siliceous uroliths.^[115]

Pelleted feeds may be conducive to formation of phosphate uroliths, because of increased urinary phosphorus excretion. This is attributable to lower saliva production where pelleted rations containing finely ground constituents are fed. With less blood phosphate partitioned into saliva, more tends to be excreted in urine.^[116] (Most saliva phosphate is fecally excreted.^[117])

Oxalate uroliths can occur in ruminants, although such problems from oxalate ingestion may be relatively uncommon. Ruminant urolithiasis associated with oxalate ingestion has been reported.^[118] However, no renal tubular damage or visible deposition of calcium oxalate crystals in kidneys was found in yearling wether sheep fed diets containing soluble oxalate at 6.5 percent of dietary dry matter for about 100 days.^[119]

Conditions limiting water intake can result in stone formation.^[120]

Various surgical interventions, e.g. amputation of the urethral process at its base near the glans penis in male ruminants, perineal urethrostomy, or tube cystostomy may be considered for relief of obstructive urolithiasis.^[120]

See also

- [Nephrocalcinosis](#)
- [Kidney disease](#)

References

1. Schulsinger DA (2014). *Kidney Stone Disease: Say NO to Stones!* (<https://books.google.com/books?id=2ADRBQAAQBAJ&pg=PA27>). Springer. p. 27. ISBN 9783319121055. Archived (<https://web.archive.org/web/20170908221053/https://books.google.com/books?id=2ADRBQAAQBAJ&pg=PA27>) from the original on 8 September 2017.
2. "Kidney Stones in Adults" (<http://www.niddk.nih.gov/health-information/health-topics/urologic-disease/kidney-stones-in-adults/Pages/facts.aspx>). February 2013. Archived (<https://web.archive.org/web/20150511192215/http://www.niddk.nih.gov/health-information/health-topics/urologic-disease/kidney-stones-in-adults/Pages/facts.aspx>) from the original on 11 May 2015. Retrieved 22 May 2015.
3. Knoll T, Pearle MS (2012). *Clinical Management of Urolithiasis* (<https://books.google.com/books?id=A2uak6SVgBUC&pg=PA21>). Springer Science & Business Media. p. 21. ISBN 9783642287329. Archived (<https://web.archive.org/web/20170908221053/https://books.google.com/books?id=A2uak6SVgBUC&pg=PA21>) from the original on 8 September 2017.
4. Qaseem A, Dallas P, Forciea MA, Starkey M, et al. (November 2014). "Dietary and pharmacologic management to prevent recurrent nephrolithiasis in adults: a clinical practice guideline from the American College of Physicians". *Annals of Internal Medicine*. **161** (9): 659–67. doi:10.7326/M13-2908 (<https://doi.org/10.7326%2FM13-2908>). PMID 25364887 (<https://pubmed.ncbi.nlm.nih.gov/25364887>).
5. Vos T, Allen C, Arora M, Barber RM, Bhutta ZA, Brown A, et al. (GBD 2015 Disease and Injury Incidence and Prevalence Collaborators) (October 2016). "Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015" (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5055577>). *Lancet*. **388** (10053): 1545–1602. doi:10.1016/S0140-6736(16)31678-6 (<https://doi.org/10.1016%2FS0140-6736%2816%2931678-6>). PMC 5055577 (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5055577>). PMID 27733282 (<https://pubmed.ncbi.nlm.nih.gov/27733282>).
6. Vos T, Allen C, Arora M, Barber RM, Bhutta ZA, Brown A, et al. (GBD 2015 Disease and Injury Incidence and Prevalence Collaborators) (October 2016). "Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015" (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5388903>). *Lancet*. **388** (10053): 1459–1544. doi:10.1016/s0140-6736(16)31012-1 (<https://doi.org/10.1016%2FS0140-6736%2816%2931012-1>). PMC 5388903 (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5388903>). PMID 27733281 (<https://pubmed.ncbi.nlm.nih.gov/27733281>).

7. Miller NL, Lingeman JE (March 2007). "Management of kidney stones" (<http://www.bmj.com/content/334/7591/468.full.pdf>) (PDF). *BMJ*. **334** (7591): 468–72. doi:10.1136/bmj.39113.480185.80 (<https://doi.org/10.1136%2Fbmj.39113.480185.80>). PMC 1808123 (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1808123>). PMID 17332586 (<https://pubmed.ncbi.nlm.nih.gov/17332586>). Archived (<https://web.archive.org/web/20101227035746/http://www.bmj.com/content/334/7591/468.full.pdf>) (PDF) from the original on 27 December 2010.
8. Morgan MS, Pearle MS (March 2016). "Medical management of renal stones". *BMJ*. **352**: i52. doi:10.1136/bmj.i52 (<https://doi.org/10.1136%2Fbmj.i52>). PMID 26977089 (<https://pubmed.ncbi.nlm.nih.gov/26977089>).
9. Afshar K, Jafari S, Marks AJ, Eftekhari A, MacNeily AE (June 2015). "Nonsteroidal anti-inflammatory drugs (NSAIDs) and non-opioids for acute renal colic". *The Cochrane Database of Systematic Reviews*. **6** (6): CD006027. doi:10.1002/14651858.CD006027.pub2 (<https://doi.org/10.1002%2F14651858.CD006027.pub2>). PMID 26120804 (<https://pubmed.ncbi.nlm.nih.gov/26120804>).
10. Wang RC, Smith-Bindman R, Whitaker E, Neilson J, Allen IE, Stoller ML, Fahimi J (March 2017). "Effect of Tamsulosin on Stone Passage for Ureteral Stones: A Systematic Review and Meta-analysis". *Annals of Emergency Medicine*. **69** (3): 353–361.e3. doi:10.1016/j.annemergmed.2016.06.044 (<https://doi.org/10.1016%2Fj.annemergmed.2016.06.044>). PMID 27616037 (<https://pubmed.ncbi.nlm.nih.gov/27616037>).
11. Preminger GM (2007). "Chapter 148: Stones in the Urinary Tract" (<http://www.merckmanuals.com/home/sec12/ch148/ch148a.html>). In Cutler RE (ed.). *The Merck Manual of Medical Information Home Edition* (3rd ed.). Whitehouse Station, New Jersey: Merck Sharp and Dohme Corporation.
12. *Nephrolithiasis~Overview* (<https://emedicine.medscape.com/article/437096-Overview>) at eMedicine § Background.
13. Pearle MS, Calhoun EA, Curhan GC (2007). "Ch. 8: Urolithiasis" (http://kidney.niddk.nih.gov/statistics/uda/Urologic_Diseases_in_America.pdf) (PDF). In Litwin MS, Saigal CS (eds.). *Urologic Diseases in America (NIH Publication No. 07–5512)*. Bethesda, Maryland: National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, United States Public Health Service, United States Department of Health and Human Services. pp. 283–319. Archived (https://web.archive.org/web/20111018023922/http://kidney.niddk.nih.gov/statistics/UDA/Urologic_Diseases_in_America.pdf) (PDF) from the original on 18 October 2011.
14. Cavendish M (2008). "Kidney disorders" (https://books.google.com/?id=L5fGm_7ThKEC&pg=PA507&lpg=PA507&dq=0761477721#v=onepage&q&f=false). *Diseases and Disorders*. **2** (1st ed.). Tarrytown, New York: Marshall Cavendish Corporation. pp. 490–3. ISBN 978-0-7614-7772-3.
15. Curhan GC, Willett WC, Rimm EB, Spiegelman D, et al. (February 1996). "Prospective study of beverage use and the risk of kidney stones" (<http://aje.oxfordjournals.org/content/143/3/240.full.pdf>) (PDF). *American Journal of Epidemiology*. **143** (3): 240–7. doi:10.1093/oxfordjournals.aje.a008734 (<https://doi.org/10.1093%2Foxfordjournals.aje.a008734>). PMID 8561157 (<https://pubmed.ncbi.nlm.nih.gov/8561157>).
16. Knight J, Assimos DG, Easter L, Holmes RP (November 2010). "Metabolism of fructose to oxalate and glycolate" (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3139422>). *Hormone and Metabolic Research = Hormon- und Stoffwechselforschung = Hormones et Metabolisme*. **42** (12): 868–73. doi:10.1055/s-0030-1265145 (<https://doi.org/10.1055%2Fs-0030-1265145>). PMC 3139422 (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3139422>). PMID 20842614 (<https://pubmed.ncbi.nlm.nih.gov/20842614>).
17. Johri N, Cooper B, Robertson W, Choong S, et al. (2010). "An update and practical guide to renal stone management" (<https://www.karger.com/Article/PDF/000317196>). *Nephron Clinical Practice*. **116** (3): c159-71. doi:10.1159/000317196 (<https://doi.org/10.1159%2F000317196>). PMID 20606476 (<https://pubmed.ncbi.nlm.nih.gov/20606476>).

18. Moe OW (January 2006). "Kidney stones: pathophysiology and medical management" (<http://emed.chris-barton.com/PDF/kidney%20stones%20pathophys%20and%20rx.pdf>) (PDF). *Lancet*. **367** (9507): 333–44. doi:10.1016/S0140-6736(06)68071-9 (<https://doi.org/10.1016%2FS0140-6736%2806%2968071-9>). PMID 16443041 (<https://pubmed.ncbi.nlm.nih.gov/16443041>). Archived (<https://web.archive.org/web/20110815154001/http://emed.chris-barton.com/PDF/kidney%20stones%20pathophys%20and%20rx.pdf>) (PDF) from the original on 15 August 2011.
19. Thakker RV (March 2000). "Pathogenesis of Dent's disease and related syndromes of X-linked nephrolithiasis" (<http://www.nature.com/ki/journal/v57/n3/pdf/4491399a.pdf>) (PDF). *Kidney International*. **57** (3): 787–93. doi:10.1046/j.1523-1755.2000.00916.x (<https://doi.org/10.1046%2Fj.1523-1755.2000.00916.x>). PMID 10720930 (<https://pubmed.ncbi.nlm.nih.gov/10720930>). Archived (<https://web.archive.org/web/20121105121823/http://www.nature.com/ki/journal/v57/n3/pdf/4491399a.pdf>) (PDF) from the original on 5 November 2012.
20. National Endocrine and Metabolic Diseases Information Service (2006). "Hyperparathyroidism (NIH Publication No. 6–3425)" (<https://web.archive.org/web/20110524101254/http://www.endocrine.niddk.nih.gov/pubs/hyper/hyper.htm>). *Information about Endocrine and Metabolic Diseases: A-Z list of Topics and Titles*. Bethesda, Maryland: National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Public Health Service, US Department of Health and Human Services. Archived from the original (<http://www.endocrine.niddk.nih.gov/pubs/hyper/hyper.htm>) on 24 May 2011. Retrieved 27 July 2011.
21. Hoppe B, Langman CB (October 2003). "A United States survey on diagnosis, treatment, and outcome of primary hyperoxaluria". *Pediatric Nephrology*. **18** (10): 986–91. doi:10.1007/s00467-003-1234-x (<https://doi.org/10.1007%2Fs00467-003-1234-x>). PMID 12920626 (<https://pubmed.ncbi.nlm.nih.gov/12920626>).
22. Reilly RF, Ch. 13: "Nephrolithiasis". In *Reilly Jr & Perazella 2005*, pp. 192–207.
23. National Kidney and Urologic Diseases Information Clearinghouse (2008). "Medullary Sponge Kidney (NIH Publication No. 08–6235)" (<https://web.archive.org/web/20110807163748/http://kidney.niddk.nih.gov/kudiseases/pubs/medullaryspongekidney/>). *Kidney & Urologic Diseases: A-Z list of Topics and Titles*. Bethesda, Maryland: National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Public Health Service, US Department of Health and Human Services. Archived from the original (<http://kidney.niddk.nih.gov/kudiseases/pubs/medullaryspongekidney/>) on 7 August 2011. Retrieved 27 July 2011.
24. National Digestive Diseases Information Clearinghouse (2006). "Crohn's Disease (NIH Publication No. 06–3410)" (<https://web.archive.org/web/20140609002323/http://digestive.niddk.nih.gov/ddiseases/pubs/crohns/>). *Digestive Diseases: A-Z List of Topics and Titles*. Bethesda, Maryland: National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, United States Public Health Service, United States Department of Health and Human Services. Archived from the original (<http://digestive.niddk.nih.gov/ddiseases/pubs/crohns/>) on 9 June 2014. Retrieved 27 July 2011.
25. Farmer RG, Mir-Madjlessi SH, Kiser WS (1974). "Urinary excretion of oxalate, calcium, magnesium, and uric acid in inflammatory bowel disease" (<http://www.ccjm.org/content/41/3/109.short>). *Cleveland Clinic Quarterly*. **41** (3): 109–17. doi:10.3949/ccjm.41.3.109 (<https://doi.org/10.3949%2Fccjm.41.3.109>). PMID 4416806 (<https://pubmed.ncbi.nlm.nih.gov/4416806>).
26. "Summary". In *Committee to Review Dietary Reference Intakes for Vitamin D and Calcium 2011*, pp. 1–14.
27. "Tolerable upper intake levels: Calcium and vitamin D". In *Committee to Review Dietary Reference Intakes for Vitamin D and Calcium 2011*, pp. 403–56.

28. Parmar MS (June 2004). "Kidney stones" (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC421787>). *BMJ*. **328** (7453): 1420–4. doi:10.1136/bmj.328.7453.1420 (<https://doi.org/10.1136%2Fbmj.328.7453.1420>). PMC 421787 (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC421787>). PMID 15191979 (<https://pubmed.ncbi.nlm.nih.gov/15191979>).
29. Liebman M, Al-Wahsh IA (May 2011). "Probiotics and other key determinants of dietary oxalate absorption" (<http://advances.nutrition.org/content/2/3/254.full.pdf>) (PDF). *Advances in Nutrition*. **2** (3): 254–60. doi:10.3945/an.111.000414 (<https://doi.org/10.3945%2Fan.111.000414>). PMC 3090165 (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3090165>). PMID 22332057 (<https://pubmed.ncbi.nlm.nih.gov/22332057>). Archived (<https://web.archive.org/web/20160116135506/http://advances.nutrition.org/content/2/3/254.full.pdf>) (PDF) from the original on 16 January 2016.
30. Committee on Fluoride in Drinking Water of the National Academy of Sciences (2006). "Chapter 9: Effects on the Renal System" (http://www.nap.edu/openbook.php?record_id=11571&page=268). *Fluoride in Drinking Water: A Scientific Review of EPA's Standards*. Washington, DC: The National Academies Press. pp. 236–48. ISBN 978-0-309-65799-0. Archived (https://web.archive.org/web/20110730220401/http://www.nap.edu/openbook.php?record_id=11571&page=268) from the original on 30 July 2011.
31. Ferraro PM, Mandel EI, Curhan GC, Gambaro G, Taylor EN (October 2016). "Dietary Protein and Potassium, Diet-Dependent Net Acid Load, and Risk of Incident Kidney Stones" (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5053786>). *Clinical Journal of the American Society of Nephrology*. **11** (10): 1834–1844. doi:10.2215/CJN.01520216 (<https://doi.org/10.2215%2FCJN.01520216>). PMC 5053786 (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5053786>). PMID 27445166 (<https://pubmed.ncbi.nlm.nih.gov/27445166>).
32. Riley JM, Kim H, Averch TD, Kim HJ (December 2013). "Effect of magnesium on calcium and oxalate ion binding" (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3883082>). *Journal of Endourology*. **27** (12): 1487–92. doi:10.1089/end.2013.0173 (<https://doi.org/10.1089%2Fend.2013.0173>). PMC 3883082 (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3883082>). PMID 24127630 (<https://pubmed.ncbi.nlm.nih.gov/24127630>).
33. Negri AL, Spivacow FR, Del Valle EE (2013). "[Diet in the treatment of renal lithiasis. Pathophysiological basis]". *Medicina*. **73** (3): 267–71. PMID 23732207 (<https://pubmed.ncbi.nlm.nih.gov/23732207>).
34. Goodwin JS, Tangum MR (November 1998). "Battling quackery: attitudes about micronutrient supplements in American academic medicine". *Archives of Internal Medicine*. **158** (20): 2187–91. doi:10.1001/archinte.158.20.2187 (<https://doi.org/10.1001%2Farchinte.158.20.2187>). PMID 9818798 (<https://pubmed.ncbi.nlm.nih.gov/9818798>).
35. Traxer O, Pearle MS, Gattegno B, Thibault P (December 2003). "[Vitamin C and stone risk. Review of the literature]". *Progres en Urologie*. **13** (6): 1290–4. PMID 15000301 (<https://pubmed.ncbi.nlm.nih.gov/15000301>).
36. Ferraro, Pietro Manuel; Curhan, Gary C.; Gambaro, Giovanni; Taylor, Eric N. (March 2016). "Total, Dietary, and Supplemental Vitamin C intake and risk of incident kidney stones" (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4769668>). *American Journal of Kidney Diseases*. **67** (3): 400–407. doi:10.1053/j.ajkd.2015.09.005 (<https://doi.org/10.1053%2Fj.ajkd.2015.09.005>). ISSN 1523-6838 (<https://www.worldcat.org/issn/1523-6838>). PMC 4769668 (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4769668>). PMID 26463139 (<https://pubmed.ncbi.nlm.nih.gov/26463139>).
37. Rodman JS, Seidman C (1996). "Ch. 8: Dietary Troublemakers" (<https://archive.org/details/nomorekidneyston0000rodman>). In Rodman JS, Seidman C, Jones R (eds.). *No More Kidney Stones* (1st ed.). New York: John Wiley & Sons, Inc. pp. 46–57. ISBN 978-0-471-12587-7.

38. Brawer MK, Makarov DV, Partin AW, Roehrborn CG, Nickel JC, Lu SH, Yoshimura N, Chancellor MB, Assimos DG (2008). "Best of the 2008 AUA Annual Meeting: Highlights from the 2008 Annual Meeting of the American Urological Association, May 17-22, 2008, Orlando, FL" (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2483319>). *Reviews in Urology*. **10** (2): 136–56. PMC 2483319 (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2483319>). PMID 18660856 (<https://pubmed.ncbi.nlm.nih.gov/18660856>).
39. Mirheydar HS, Banapour P, Massoudi R, Palazzi KL, Jabaji R, Reid EG, Millard FE, Kane CJ, Sur RL (December 2014). "What is the incidence of kidney stones after chemotherapy in patients with lymphoproliferative or myeloproliferative disorders?". *International Brazilian Journal of Urology*. **40** (6): 772–80. doi:10.1590/S1677-5538.IBJU.2014.06.08 (<https://doi.org/10.1590%2FS1677-5538.IBJU.2014.06.08>). PMID 25615245 (<https://pubmed.ncbi.nlm.nih.gov/25615245>).
40. Caudarella R, Vescini F (September 2009). "Urinary citrate and renal stone disease: the preventive role of alkali citrate treatment". *Archivio Italiano di Urologia, Andrologia*. **81** (3): 182–7. PMID 19911682 (<https://pubmed.ncbi.nlm.nih.gov/19911682>).
41. Perazella MA, Ch. 14: "Urinalysis". In [Reilly Jr & Perazella 2005](#), pp. 209–26.
42. Knudsen BE, Beiko DT, Denstedt JD, Ch. 16: "Uric Acid Urolithiasis". In [Stoller & Meng 2007](#), pp. 299–308.
43. *Nephrolithiasis~Overview* (<https://emedicine.medscape.com/article/437096-Overview>) at eMedicine § Pathophysiology.
44. Coe FL, Evan A, Worcester E (October 2005). "Kidney stone disease" (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1236703>). *The Journal of Clinical Investigation*. **115** (10): 2598–608. doi:10.1172/JCI26662 (<https://doi.org/10.1172%2FJCI26662>). PMC 1236703 (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1236703>). PMID 16200192 (<https://pubmed.ncbi.nlm.nih.gov/16200192>).
45. del Valle EE, Spivacow FR, Negri AL (2013). "[Citrate and renal stones]". *Medicina*. **73** (4): 363–8. PMID 23924538 (<https://pubmed.ncbi.nlm.nih.gov/23924538>).
46. Anoaia EJ, Paik ML, Resnick MI (2009). "Ch. 7: Anatomic Nephrolithomy" (<https://books.google.com/?id=GahMzaKgMKAC&pg=PA45&lpg=PA45&dq=nephrolithiasis+diagnosis+radio+graphic#v=onepage&q=nephrolithiasis%20diagnosis%20radiographic&f=false>). In Graham SD, Keane TE (eds.). *Glenn's Urologic Surgery* (7th ed.). Philadelphia: Lippincott Williams & Wilkins. pp. 45–50. ISBN 978-0-7817-9141-0.
47. Weaver SH, Jenkins P (2002). "Ch. 14: Renal and Urological Care" (<https://archive.org/details/illustratedmanua0000unse>). *Illustrated Manual of Nursing Practice* (3rd ed.). Lippincott Williams & Wilkins. ISBN 978-1-58255-082-4.
48. American College of Emergency Physicians (27 October 2014). "Ten Things Physicians and Patients Should Question" (<http://www.choosingwisely.org/doctor-patient-lists/american-college-of-emergency-physicians/>). *Choosing Wisely*. Archived (<https://web.archive.org/web/20140307012443/http://www.choosingwisely.org/doctor-patient-lists/american-college-of-emergency-physicians/>) from the original on 7 March 2014. Retrieved 14 January 2015.
49. "American Urological Association | Choosing Wisely" (<http://www.choosingwisely.org/societies/american-urological-association/>). *www.choosingwisely.org*. Archived (<https://web.archive.org/web/20170223133729/http://www.choosingwisely.org/societies/american-urological-association/>) from the original on 23 February 2017. Retrieved 28 May 2017.
50. Smith RC, Varanelli M (July 2000). "Diagnosis and management of acute ureterolithiasis: CT is truth". *AJR. American Journal of Roentgenology*. **175** (1): 3–6. doi:10.2214/ajr.175.1.1750003 (<https://doi.org/10.2214%2Fajr.175.1.1750003>). PMID 10882237 (<https://pubmed.ncbi.nlm.nih.gov/10882237>).

51. Fang L (2009). "Chapter 135: Approach to the Patient with Nephrolithiasis" (<https://books.google.com/?id=blZvJPcSEXMC&pg=PA964&lpg=PA964&dq=nephrolithiasis+%22physical+examination%22#v=onepage&q=nephrolithiasis%20%22physical%20examination%22&f=false>). In Goroll AH, Mulley AG (eds.). *Primary care medicine: office evaluation and management of the adult patient* (6th ed.). Philadelphia: Lippincott Williams & Wilkins. pp. 962–7. ISBN 978-0-7817-7513-7.
52. Pietrow PK, Karellas ME (July 2006). "Medical management of common urinary calculi" (<http://www.aafp.org/afp/2006/0701/p86.pdf>) (PDF). *American Family Physician*. **74** (1): 86–94. PMID 16848382 (<https://pubmed.ncbi.nlm.nih.gov/16848382>). Archived (<https://web.archive.org/web/20111123060406/http://www.aafp.org/afp/2006/0701/p86.pdf>) (PDF) from the original on 23 November 2011.
53. Bushinsky D, Coe FL, Moe OW (2007). "Ch. 37: Nephrolithiasis" (<https://web.archive.org/web/20111008090923/http://www.expertconsultbook.com/expertconsult/op/book.do?method=display&type=bookPage&decorator=none&eid=4-u1.0-B978-1-4160-3105-5..50039-6&isbn=978-1-4160-3105-5#lpState=open&lpTab=contentsTab&content=4-u1.0-B978-1-4160-3105-5..50039-6%3Bfrom%3Dtoc%3Btype%3DbookPage%3Bisbn%3D978-1-4160-3105-5&search=none>). In Brenner BM (ed.). *Brenner and Rector's The Kidney*. **1** (8th ed.). Philadelphia: WB Saunders. pp. 1299–349. ISBN 978-1-4160-3105-5. Archived from the original (<http://www.expertconsultbook.com/expertconsult/op/book.do?method=display&type=bookPage&decorator=none&eid=4-u1.0-B978-1-4160-3105-5..50039-6&isbn=978-1-4160-3105-5#lpState=open&lpTab=contentsTab&content=4-u1.0-B978-1-4160-3105-5..50039-6%3Bfrom%3Dtoc%3Btype%3DbookPage%3Bisbn%3D978-1-4160-3105-5&search=none>) on 8 October 2011.
54. Smith RC, Levine J, Rosenfeld AT (September 1999). "Helical CT of urinary tract stones. Epidemiology, origin, pathophysiology, diagnosis, and management". *Radiologic Clinics of North America*. **37** (5): 911–52, v. doi:10.1016/S0033-8389(05)70138-X ([https://doi.org/10.1016/S0033-8389\(05\)70138-X](https://doi.org/10.1016/S0033-8389(05)70138-X)). PMID 10494278 (<https://pubmed.ncbi.nlm.nih.gov/10494278>).
55. Semins, Michelle; Matlaga, Brian (2013). "Management of urolithiasis in pregnancy" (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3792830>). *International Journal of Women's Health*: 599. doi:10.2147/ijwh.s51416 (<https://doi.org/10.2147/ijwh.s51416>). ISSN 1179-1411 (<https://www.worldcat.org/issn/1179-1411>). PMC 3792830 (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3792830>). PMID 24109196 (<https://pubmed.ncbi.nlm.nih.gov/24109196>).
56. Smith-Bindman R, Aubin C, Bailitz J, Bengiamin RN, Camargo CA, Corbo J, et al. (September 2014). "Ultrasonography versus computed tomography for suspected nephrolithiasis" (<https://escholarship.org/content/qt1cm5f8cd/qt1cm5f8cd.pdf?t=nwl44w>) (PDF). *The New England Journal of Medicine*. **371** (12): 1100–10. doi:10.1056/NEJMoa1404446 (<https://doi.org/10.1056/NEJMoa1404446>). PMID 25229916 (<https://pubmed.ncbi.nlm.nih.gov/25229916>).
57. National Kidney and Urologic Diseases Information Clearinghouse (2007). "Kidney Stones in Adults (NIH Publication No. 08–2495)" (<https://web.archive.org/web/20110726181803/http://kidney.niddk.nih.gov/kudiseases/pubs/stonesadults/>). *Kidney & Urologic Diseases: A-Z list of Topics and Titles*. Bethesda, Maryland: National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Public Health Service, US Department of Health and Human Services. Archived from the original (<http://kidney.niddk.nih.gov/kudiseases/pubs/stonesadults/>) on 26 July 2011. Retrieved 27 July 2011.
58. Becker KL (2001). *Principles and practice of endocrinology and metabolism* (<https://books.google.com/books?id=FVfzRvaucq8C&pg=PA684>) (3 ed.). Philadelphia, Pa. [u.a.]: Lippincott, Williams & Wilkins. p. 684. ISBN 978-0-7817-1750-2. Archived (<https://web.archive.org/web/20170908221053/https://books.google.com/books?id=FVfzRvaucq8C&pg=PA684>) from the original on 8 September 2017.

59. "Cystine stones" (<http://www.uptodate.com/contents/cystine-stones>). *UpToDate*. Archived (<https://web.archive.org/web/20140226110022/http://www.uptodate.com/contents/cystine-stones>) from the original on 26 February 2014. Retrieved 20 February 2014.
60. Bailey & Love's/25th/1296
61. National Endocrine and Metabolic Diseases Information Service (2008). "Renal Tubular Acidosis (NIH Publication No. 09–4696)" (<https://web.archive.org/web/20110728025351/http://kidney.niddk.nih.gov/kudiseases/pubs/tubularacidosis/>). *Kidney & Urologic Diseases: A-Z list of Topics and Titles*. Bethesda, Maryland: National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Public Health Service, US Department of Health and Human Services. Archived from the original (<http://kidney.niddk.nih.gov/kudiseases/pubs/tubularacidosis/>) on 28 July 2011. Retrieved 27 July 2011.
62. De Mais D (2009). *ASCP Quick Compendium of Clinical Pathology* (2nd ed.). Chicago: ASCP Press.
63. Weiss M, Liapis H, Tomaszewski JE, Arend LJ (2007). "Chapter 22: Pyelonephritis and Other Infections, Reflux Nephropathy, Hydronephrosis, and Nephrolithiasis" (<https://books.google.com/?id=oWymx2hp1OoC&pg=PA886&lpg=PA886&dq=%22AA+amyloidosis%22+pyelonephritis#v=onepage&q=%22AA%20amyloidosis%22%20pyelonephritis&f=false>). In Jennette JC, Olson JL, Schwartz MM, Silva FG (eds.). *Heptinstall's Pathology of the Kidney*. 2 (6th ed.). Philadelphia: Lippincott Williams & Wilkins. pp. 991–1082. ISBN 978-0-7817-4750-9.
64. Halabe A, Sperling O (1994). "Uric acid nephrolithiasis". *Mineral and Electrolyte Metabolism*. **20** (6): 424–31. PMID 7783706 (<https://pubmed.ncbi.nlm.nih.gov/7783706/>).
65. Kamatani N (December 1996). "[Adenine phosphoribosyltransferase(APRT) deficiency]". *Nihon Rinsho. Japanese Journal of Clinical Medicine* (in Japanese). **54** (12): 3321–7. PMID 8976113 (<https://pubmed.ncbi.nlm.nih.gov/8976113/>).
66. Rosenberg LE, Durant JL, Elsas LJ (June 1968). "Familial iminoglycinuria. An inborn error of renal tubular transport". *The New England Journal of Medicine*. **278** (26): 1407–13. doi:10.1056/NEJM196806272782601 (<https://doi.org/10.1056%2FNEJM196806272782601>). PMID 5652624 (<https://pubmed.ncbi.nlm.nih.gov/5652624/>).
67. Coşkun T, Ozalp I, Tokatli A (1993). "Iminoglycinuria: a benign type of inherited aminoaciduria". *The Turkish Journal of Pediatrics*. **35** (2): 121–5. PMID 7504361 (<https://pubmed.ncbi.nlm.nih.gov/7504361/>).
68. Merck Sharp; Dohme Corporation (2010). "Patient Information about Crixivan for HIV (Human Immunodeficiency Virus) Infection" (http://www.merck.com/product/usa/pi_circulars/c/crixivan/crixivan_ppi.pdf) (PDF). *Crixivan® (indinavir sulfate) Capsules*. Whitehouse Station, New Jersey: Merck Sharp & Dohme Corporation. Archived (https://web.archive.org/web/20110815003924/http://www.merck.com/product/usa/pi_circulars/c/crixivan/crixivan_ppi.pdf) (PDF) from the original on 15 August 2011. Retrieved 27 July 2011.
69. Schlossberg D, Samuel R (2011). "Sulfadiazine" (https://books.google.com/books/about/Antibiotic_Manual.html?id=sCXn0xOVKNoC). *Antibiotic Manual: A Guide to Commonly Used Antimicrobials* (1st ed.). Shelton, Connecticut: People's Medical Publishing House. pp. 411–12. ISBN 978-1-60795-084-4.
70. Carr MC, Prien EL, Babayan RK (December 1990). "Triamterene nephrolithiasis: renewed attention is warranted". *The Journal of Urology*. **144** (6): 1339–40. doi:10.1016/S0022-5347(17)39734-3 (<https://doi.org/10.1016%2FS0022-5347%2817%2939734-3>). PMID 2231920 (<https://pubmed.ncbi.nlm.nih.gov/2231920/>).
71. McNutt WF (1893). "Chapter VII: Vesical Calculi (Cysto-lithiasis)" (<https://books.google.com/?id=RP0oAAAAYAAJ&pg=PA185&lpg=PA185&dq=cystolithiasis+symptoms#v=onepage&q&f=false>). *Diseases of the Kidneys and Bladder: A Text-book for Students of Medicine*. IV: Diseases of the Bladder. Philadelphia: J.B. Lippincott Company. pp. 185–6.

72. Gettman MT, Segura JW (March 2005). "Management of ureteric stones: issues and controversies". *BJU International*. 95 Suppl 2 (Supplement 2): 85–93. doi:10.1111/j.1464-410X.2005.05206.x (<https://doi.org/10.1111%2Fj.1464-410X.2005.05206.x>). PMID 15720341 (<https://pubmed.ncbi.nlm.nih.gov/15720341>).
73. Segura, Joseph W. (1997). "Staghorn Calculi". *Urologic Clinics of North America*. 24 (1): 71–80. doi:10.1016/S0094-0143(05)70355-4 (<https://doi.org/10.1016%2FS0094-0143%2805%2970355-4>). ISSN 0094-0143 (<https://www.worldcat.org/issn/0094-0143>). PMID 9048853 (<https://pubmed.ncbi.nlm.nih.gov/9048853>).
74. Fink HA, Wilt TJ, Eidman KE, Garimella PS, et al. (April 2013). "Medical management to prevent recurrent nephrolithiasis in adults: a systematic review for an American College of Physicians Clinical Guideline". *Annals of Internal Medicine*. 158 (7): 535–43. doi:10.7326/0003-4819-158-7-201304020-00005 (<https://doi.org/10.7326%2F0003-4819-158-7-201304020-00005>). PMID 23546565 (<https://pubmed.ncbi.nlm.nih.gov/23546565>).
75. Qaseem A, Dallas P, Forciea MA, Starkey M, Denberg TD (November 2014). "Dietary and pharmacologic management to prevent recurrent nephrolithiasis in adults: a clinical practice guideline from the American College of Physicians". *Annals of Internal Medicine*. 161 (9): 659–67. doi:10.7326/m13-2908 (<https://doi.org/10.7326%2Fm13-2908>). PMID 25364887 (<https://pubmed.ncbi.nlm.nih.gov/25364887>).
76. Goldfarb DS, Coe FL (November 1999). "Prevention of recurrent nephrolithiasis" (<http://www.aafp.org/afp/991115ap/2269.html>). *American Family Physician*. 60 (8): 2269–76. PMID 10593318 (<https://pubmed.ncbi.nlm.nih.gov/10593318>). Archived (<https://web.archive.org/web/20050822183805/http://www.aafp.org/afp/991115ap/2269.html>) from the original on 22 August 2005.
77. Finkelstein VA, Goldfarb DS (May 2006). "Strategies for preventing calcium oxalate stones" (<http://www.cmaj.ca/cgi/reprint/174/10/1407>). *CMAJ*. 174 (10): 1407–9. doi:10.1503/cmaj.051517 (<https://doi.org/10.1503%2Fcmaj.051517>). PMC 1455427 (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1455427>). PMID 16682705 (<https://pubmed.ncbi.nlm.nih.gov/16682705>). Archived (<https://web.archive.org/web/20081015202450/http://www.cmaj.ca/cgi/reprint/174/10/1407>) from the original on 15 October 2008.
78. Fink HA, Wilt TJ, Eidman KE, Garimella PS, MacDonald R, Rutks IR, Brasure M, Kane RL, Monga M (July 2012). "Recurrent Nephrolithiasis in Adults: Comparative Effectiveness of Preventive Medical Strategies". PMID 22896859 (<https://pubmed.ncbi.nlm.nih.gov/22896859>).
79. "What are kidney stones?" (<http://www.kidney.org.au/ForPatients/Management/KidneyStones/tabid/838/Default.aspx>). *kidney.org*. Archived (<https://web.archive.org/web/20130514122900/http://kidney.org.au/ForPatients/Management/KidneyStones/tabid/838/Default.aspx>) from the original on 14 May 2013. Retrieved 19 August 2013.
80. Taylor EN, Curhan GC (September 2006). "Diet and fluid prescription in stone disease". *Kidney International*. 70 (5): 835–9. doi:10.1038/sj.ki.5001656 (<https://doi.org/10.1038%2Fs00167-006-0165-6>). PMID 16837923 (<https://pubmed.ncbi.nlm.nih.gov/16837923>).
81. Heaney RP (March 2006). "Nutrition and chronic disease" (<https://www.webcitation.org/60DJf9pe8?url=http://www.mayoclinicproceedings.com/content/81/3/297.full.pdf>) (PDF). *Mayo Clinic Proceedings*. 81 (3): 297–9. doi:10.4065/81.3.297 (<https://doi.org/10.4065%2F81.3.297>). PMID 16529131 (<https://pubmed.ncbi.nlm.nih.gov/16529131>). Archived from the original (<http://www.mayoclinicproceedings.com/content/81/3/297.full.pdf>) (PDF) on 16 July 2011.
82. Tiselius HG (May 2003). "Epidemiology and medical management of stone disease". *BJU International*. 91 (8): 758–67. doi:10.1046/j.1464-410X.2003.04208.x (<https://doi.org/10.1046%2Fj.1464-410X.2003.04208.x>). PMID 12709088 (<https://pubmed.ncbi.nlm.nih.gov/12709088>).

83. Taylor EN, Stampfer MJ, Curhan GC (December 2004). "Dietary factors and the risk of incident kidney stones in men: new insights after 14 years of follow-up" (<http://jasn.asnjournals.org/content/15/12/3225.full.pdf>) (PDF). *Journal of the American Society of Nephrology*. **15** (12): 3225–32. doi:10.1097/01.ASN.0000146012.44570.20 (<https://doi.org/10.1097%2F01.ASN.0000146012.44570.20>). PMID 15579526 (<https://pubmed.ncbi.nlm.nih.gov/15579526>).
84. Cicerello E, Merlo F, Maccatrozzo L (September 2010). "Urinary alkalization for the treatment of uric acid nephrolithiasis". *Archivio Italiano di Urologia, Andrologia*. **82** (3): 145–8. PMID 21121431 (<https://pubmed.ncbi.nlm.nih.gov/21121431>).
85. Cameron JS, Simmonds HA (June 1987). "Use and abuse of allopurinol" (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1246665>). *British Medical Journal*. **294** (6586): 1504–5. doi:10.1136/bmj.294.6586.1504 (<https://doi.org/10.1136%2Fbmj.294.6586.1504>). PMC 1246665 (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1246665>). PMID 3607420 (<https://pubmed.ncbi.nlm.nih.gov/3607420>).
86. Macaluso JN (November 1996). "Management of stone disease--bearing the burden". *The Journal of Urology*. **156** (5): 1579–80. doi:10.1016/S0022-5347(01)65452-1 (<https://doi.org/10.1016%2FS0022-5347%2801%2965452-1>). PMID 8863542 (<https://pubmed.ncbi.nlm.nih.gov/8863542>).
87. Pathan SA, Mitra B, Cameron PA (April 2018). "A Systematic Review and Meta-analysis Comparing the Efficacy of Nonsteroidal Anti-inflammatory Drugs, Opioids, and Paracetamol in the Treatment of Acute Renal Colic". *European Urology*. **73** (4): 583–595. doi:10.1016/j.eururo.2017.11.001 (<https://doi.org/10.1016%2Fj.eururo.2017.11.001>). PMID 29174580 (<https://pubmed.ncbi.nlm.nih.gov/29174580>).
88. Seitz C, Liatsikos E, Porpiglia F, Tiselius HG, et al. (September 2009). "Medical therapy to facilitate the passage of stones: what is the evidence?". *European Urology*. **56** (3): 455–71. doi:10.1016/j.eururo.2009.06.012 (<https://doi.org/10.1016%2Fj.eururo.2009.06.012>). PMID 19560860 (<https://pubmed.ncbi.nlm.nih.gov/19560860>).
89. Campschroer T, Zhu X, Vernooij RW, Lock MT (April 2018). "Alpha-blockers as medical expulsive therapy for ureteral stones" (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6494465>). *The Cochrane Database of Systematic Reviews*. **4**: CD008509. doi:10.1002/14651858.CD008509.pub3 (<https://doi.org/10.1002%2F14651858.CD008509.pub3>). PMC 6494465 (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6494465>). PMID 29620795 (<https://pubmed.ncbi.nlm.nih.gov/29620795>).
90. Shock Wave Lithotripsy Task Force (2009). "Current Perspective on Adverse Effects in Shock Wave Lithotripsy" (<https://web.archive.org/web/20130718072759/http://www.auanet.org/common/pdf/education/clinical-guidance/Shock-Wave-Therapy-WP.pdf>) (PDF). *Clinical Guidelines*. Linthicum, Maryland: American Urological Association. Archived from the original (<https://www.auanet.org/common/pdf/education/clinical-guidance/Shock-Wave-Therapy-WP.pdf>) (PDF) on 18 July 2013. Retrieved 13 October 2015.
91. Lingeman JE, Matlaga BR, Evan AP (2007). "Surgical Management of Urinary Lithiasis". In Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA (eds.). *Campbell-Walsh Urology*. Philadelphia: W. B. Saunders. pp. 1431–1507.
92. Preminger GM, Tiselius HG, Assimos DG, Alken P, Buck C, Gallucci M, Knoll T, Lingeman JE, Nakada SY, Pearle MS, Sarica K, Türk C, Wolf JS (December 2007). "2007 guideline for the management of ureteral calculi". *The Journal of Urology*. **178** (6): 2418–34. doi:10.1016/j.juro.2007.09.107 (<https://doi.org/10.1016%2Fj.juro.2007.09.107>). PMID 17993340 (<https://pubmed.ncbi.nlm.nih.gov/17993340>).
93. Evan AP, McAteer JA (1996). "Ch. 28: Q-effects of Shock Wave Lithotripsy". In Coe FL, Favus MJ, Pak CY, Parks JH, Preminger GM (eds.). *Kidney Stones: Medical and Surgical Management*. Philadelphia: Lippincott-Raven. pp. 549–60.
94. Evan AP, Willis LR (2007). "Ch. 41: Extracorporeal Shock Wave Lithotripsy: Complications". In Smith AD, Badlani GH, Bagley DH, Clayman RV, Docimo SG (eds.). *Smith's Textbook on Endourology*. Hamilton, Ontario, Canada: B C Decker, Inc. pp. 353–65.

95. Young JG, Keeley FX, Ch. 38: "Indications for Surgical Removal, Including Asymptomatic Stones". In Rao, Preminger & Kavanagh 2011, pp. 441–54.
96. Wynberg JB, Borin JF, Vicena JZ, Hannosh V, Salmon SA (October 2012). "Flexible ureteroscopy-directed retrograde nephrostomy for percutaneous nephrolithotomy: description of a technique". *Journal of Endourology*. **26** (10): 1268–74. doi:10.1089/end.2012.0160 (<https://doi.org/10.1089%2Fend.2012.0160>). PMID 22563900 (<https://pubmed.ncbi.nlm.nih.gov/22563900>).
97. Lam JS, Gupta M, Ch. 25: "Ureteral Stents". In Stoller & Meng 2007, pp. 465–83.
98. Marks AJ, Qiu J, Milner TE, Chan KF, Teichman JM, Ch. 26: "Laser Lithotripsy Physics". In Rao, Preminger & Kavanagh 2011, pp. 301–10.
99. Romero V, Akpinar H, Assimos DG (2010). "Kidney stones: a global picture of prevalence, incidence, and associated risk factors" (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2931286>). *Reviews in Urology*. **12** (2–3): e86–96. PMC 2931286 (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2931286>). PMID 20811557 (<https://pubmed.ncbi.nlm.nih.gov/20811557>).
100. Lieske JC, Segura JW (2004). "Ch. 7: Evaluation and Medical Management of Kidney Stones". In Potts JM (ed.). *Essential Urology: A Guide to Clinical Practice* (1st ed.). Totowa, New Jersey: Humana Press. pp. 117–52. ISBN 978-1-58829-109-7.
101. Lozano R, Naghavi M, Foreman K, Lim S, et al. (December 2012). "Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010". *Lancet*. **380** (9859): 2095–128. doi:10.1016/S0140-6736(12)61728-0 (<https://doi.org/10.1016%2FS0140-6736%2812%2961728-0>). hdl:10536/DRO/DU:30050819 (<https://hdl.handle.net/10536%2FDRO%2FDU%3A30050819>). PMID 23245604 (<https://pubmed.ncbi.nlm.nih.gov/23245604>).
102. Windus D (2008). *The Washington manual nephrology subspecialty consult* (<https://books.google.com/books?id=sPgGqotdzqAC&pg=PA235>) (2nd ed.). Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins Health. p. 235. ISBN 978-0-7817-9149-6. Archived (<https://web.archive.org/web/20160909114412/https://books.google.com/books?id=sPgGqotdzqAC&pg=PA235>) from the original on 9 September 2016.
103. Eknoyan, G (2004). "History of urolithiasis". *Clinical Reviews in Bone and Mineral Metabolism*. **2** (3): 177–85. doi:10.1385/BMM:2:3:177 (<https://doi.org/10.1385%2FBMM%3A2%3A3%3A177>). ISSN 1534-8644 (<https://www.worldcat.org/issn/1534-8644>).
104. Celsus AC (1831). "Book VII, Chapter XXVI: Of the operation necessary in a suppression of urine, and lithotomy" (<https://books.google.com/books?id=p2kFAAAAQAAJ&pg=PA311#v=onepage&q&f=false>). In Collier GF (ed.). *A translation of the eight books of Aul. Corn. Celsus on medicine* (2nd ed.). London: Simpkin and Marshall. pp. 306–14. Archived (<https://web.archive.org/web/20140708104311/http://books.google.com/books?id=p2kFAAAAQAAJ&pg=PA311#v=onepage&q&f=false>) from the original on 8 July 2014.
105. Shah J, Whitfield HN (May 2002). "Urolithiasis through the ages". *BJU International*. **89** (8): 801–10. doi:10.1046/j.1464-410X.2002.02769.x (<https://doi.org/10.1046%2Fj.1464-410X.2002.02769.x>). PMID 11972501 (<https://pubmed.ncbi.nlm.nih.gov/11972501>).
106. Ellis H (1969). *A History of Bladder Stone*. Oxford, England: Blackwell Scientific Publications. ISBN 978-0-632-06140-2.
107. Bigelow HJ (1878). *Litholapaxy or rapid lithotripsy with evacuation* (<https://books.google.com/?id=UUKSAAAAYAAJ&printsec=frontcover#v=onepage&q&f=false>). Boston: A. Williams and Company. p. 29.
108. Marks AR, Neill US, Coe FL, Evan A, Worcester E, eds. (2008). "Chapter 114: Kidney stone disease" (<https://books.google.com/books?vid=ISBN0763750832>). *Science in medicine: the JCI textbook of molecular medicine*. Part II: Kidney and urinary tract (1st ed.). Sudbury, Massachusetts: Jones and Bartlett Publishers. pp. 898–908. ISBN 978-0-7637-5083-1. Archived (<https://web.archive.org/web/20160909062951/https://books.google.com/books?vid=ISBN0763750832>) from the original on 9 September 2016.

109. Dwyer ME, Krambeck AE, Bergstralh EJ, Milliner DS, Lieske JC, Rule AD (July 2012). "Temporal trends in incidence of kidney stones among children: a 25-year population based study" (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3482509>). *The Journal of Urology*. **188** (1): 247–52. doi:10.1016/j.juro.2012.03.021 (<https://doi.org/10.1016%2Fj.juro.2012.03.021>). PMC 3482509 (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3482509>). PMID 22595060 (<https://pubmed.ncbi.nlm.nih.gov/22595060>).
110. "Diet and Definition of Kidney Stones, Renal Calculi" (https://web.archive.org/web/20071117030318/http://www.pediatriconcall.com/fordocor/DiseasesandCondition/Diet_diseases/diet_for_renal.asp). Archived from the original (http://www.pediatriconcall.com/fordocor/DiseaseandCondition/Diet_diseases/diet_for_renal.asp) on 17 November 2007. Retrieved 11 October 2013.
111. Kirejczyk JK, Porowski T, Filonowicz R, Kazberuk A, Stefanowicz M, Wasilewska A, Debek W (February 2014). "An association between kidney stone composition and urinary metabolic disturbances in children". *Journal of Pediatric Urology*. **10** (1): 130–5. doi:10.1016/j.jpuro.2013.07.010 (<https://doi.org/10.1016%2Fj.jpuro.2013.07.010>). PMID 23953243 (<https://pubmed.ncbi.nlm.nih.gov/23953243>).
112. Pugh DG, Baird N (27 May 2012). *Sheep & Goat Medicine - E-Book* (<https://books.google.com/books?id=s-Z311q6ClcC&printsec=frontcover#v=onepage&q=uroliths&f=false>). Elsevier Health Sciences. ISBN 978-1-4377-2354-0.
113. Bushman DH, Emerick RJ, Embry LB (December 1965). "Experimentally induced ovine phosphatic urolithiasis: relationships involving dietary calcium, phosphorus and magnesium". *The Journal of Nutrition*. **87** (4): 499–504. doi:10.1093/jn/87.4.499 (<https://doi.org/10.1093%2Fjn%2F87.4.499>). PMID 5841867 (<https://pubmed.ncbi.nlm.nih.gov/5841867>).
114. Stewart SR, Emerick RJ, Pritchard RH (1991). "Effects of dietary ammonium chloride and variations in calcium to phosphorus ratio on silica urolithiasis in sheep". *J. Anim. Sci.* **69** (5): 2225–2229. doi:10.2527/1991.6952225x (<https://doi.org/10.2527%2F1991.6952225x>). PMID 1648554 (<https://pubmed.ncbi.nlm.nih.gov/1648554>).
115. Forman SA, Whiting F, Connell R (1959). "Silica urolithiasis in beef cattle. 3. Chemical and physical composition of the uroliths" (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1581990>). *Can. J. Comp. Med.* **23** (4): 157–162. PMC 1581990 (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1581990>). PMID 17649146 (<https://pubmed.ncbi.nlm.nih.gov/17649146>).
116. Scott D, Buchan W (1988). "The effects of feeding pelleted diets made from either coarsely or finely ground hay on phosphorus balance and on the partition of phosphorus excretion between urine and faeces in the sheep". *Q. J. Exp. Physiol.* **73** (3): 315–322. doi:10.1113/expphysiol.1988.sp003148 (<https://doi.org/10.1113%2Fexpphysiol.1988.sp003148>). PMID 3399614 (<https://pubmed.ncbi.nlm.nih.gov/3399614>).
117. Bravo D, Sauvart D, Bogaert C, Meschy F (2003). "III. Quantitative aspects of phosphorus excretion in ruminants" (<https://hal.archives-ouvertes.fr/hal-00900449/file/hal-00900449.pdf>) (PDF). *Reproduction, Nutrition, Development*. **43** (3): 285–300. doi:10.1051/rnd:2003021 (<https://doi.org/10.1051%2Frnd%3A2003021>). PMID 14620634 (<https://pubmed.ncbi.nlm.nih.gov/14620634>).
118. Waltner-Toews, D. and D. H. Meadows. 1980. Case report: Urolithiasis in a herd of beef cattle associated with oxalate ingestion. *Can. Vet. J.* **21**: 61-62
119. James LF, Butcher JE (1972). "Halogeton poisoning of sheep: effect of high level oxalate intake". *J. Animal Sci.* **35** (6): 1233–1238. doi:10.2527/jas1972.3561233x (<https://doi.org/10.2527%2Fjas1972.3561233x>). PMID 4647453 (<https://pubmed.ncbi.nlm.nih.gov/4647453>).
120. Kahn, C. M. (ed.) 2005. Merck veterinary manual. 9th Ed. Merck & Co., Inc., Whitehouse Station.

Notes

- Committee to Review Dietary Reference Intakes for Vitamin D and Calcium, Institute of Medicine of the National Academies (2011). Ross AC, Taylor CL, Yaktine AL, Del HB (eds.). *Dietary Reference Intakes for Calcium and Vitamin D* (http://www.nap.edu/catalog.php?record_id=13050). Washington, DC: The National Academies Press. doi:10.17226/13050 (<https://doi.org/10.17226%2F13050>). ISBN 978-0-309-16394-1. PMID 21796828 (<https://pubmed.ncbi.nlm.nih.gov/21796828>).
- Marks AJ, Qiu J, Milner TE, Chan KF, Teichman JM (2011). "Laser Lithotripsy Physics" (<http://books.google.com/?id=LJy5XJOkSkC&pg=PA302&lpg=PA302>). In Rao PN, Preminger GM, Kavanagh JP (eds.). *Urinary Tract Stone Disease* (1st ed.). London: Springer-Verlag. pp. 301–309. doi:10.1007/978-1-84800-362-0_26 (https://doi.org/10.1007%2F978-1-84800-362-0_26). ISBN 978-1-84800-361-3.
- Reilly RF, Perazella MA, eds. (2005). *Nephrology in 30 Days* (https://books.google.com/?id=tBGhK_1L6rAC&pg=PA195) (1st ed.). New York: The McGraw-Hill Companies, Inc. ISBN 978-0-07-143701-1.
- Stoller ML, Meng MV, eds. (2007). *Urinary stone disease: the practical guide to medical and surgical management* (<https://books.google.com/?id=90CO-NgKrj4C&pg=PA480>) (1st ed.). Totowa, New Jersey: Humana Press. ISBN 978-1-59259-972-1.

External links

- [Kidney stone disease \(https://curlie.org/Health/Conditions_and_Diseases/Genitourinary_Disorders/Kidney/Stones/\)](https://curlie.org/Health/Conditions_and_Diseases/Genitourinary_Disorders/Kidney/Stones/) at Curlie
- [Information from the European Urological Association \(http://patients.uroweb.org/i-am-a-urology-patient/kidney-and-ureteral-stones/\)](http://patients.uroweb.org/i-am-a-urology-patient/kidney-and-ureteral-stones/)
- [Kidney Stone Guide Book \(https://kidneystones.uchicago.edu/kidney-stone-book/\)](https://kidneystones.uchicago.edu/kidney-stone-book/) University of Chicago Kidney Stone Program

Classification **ICD-10:** N20.0 (<http://apps.who.int/classifications/icd10/browse/2016/en#/N20.0>) – N20.9 (<http://apps.who.int/classifications/icd10/browse/2016/en#/N20.9>) • **ICD-9-CM:** 592.0 (<http://www.icd9data.com/getICD9Code.ashx?icd9=592.0>) – 594.9 (<http://www.icd9data.com/getICD9Code.ashx?icd9=594.9>) • **OMIM:** 167030 (<https://omim.org/entry/167030>) • **MeSH:** D052878 (https://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&term=D052878) • **DiseasesDB:** 11346 (<http://www.diseasesdatabase.com/ddb11346.htm>)

**External
resources****MedlinePlus:**

000458 (<https://www.nlm.nih.gov/medlineplus/ency/article/000458.htm>) •

eMedicine:

med/1600 (<https://emedicine.medscape.com/med/1600-overview>) • **Patient**

UK: Kidney stone disease (<https://patient.info/doctor/urinary-tract-stones-urolithiasis>)

Retrieved from "https://en.wikipedia.org/w/index.php?title=Kidney_stone_disease&oldid=934010292"

This page was last edited on 4 January 2020, at 06:28 (UTC).

Text is available under the [Creative Commons Attribution-ShareAlike License](#); additional terms may apply. By using this site, you agree to the [Terms of Use](#) and [Privacy Policy](#). Wikipedia® is a registered trademark of the [Wikimedia Foundation, Inc.](#), a non-profit organization.